Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL): a computational method.

Biologically based models with physiological parameters are becoming more popular as a tool to estimate target tissue doses from chemical exposures. However, the majority of current physiologically based pharmacokinetic (PBPK) models do not take into account the uncertainty and/or variability within the various model parameters. Consideration of uncertainty is important to evaluate the predictive ability and complexity of a model as well as identification of parameters which contribute disproportionately to variability in model output. In order to estimate the uncertainty in PBPK model output, a versatile and simple computational method is presented which can be readily incorporated into the majority of PBPK models without extensive additions to model computer code. In this paper, a separate computer program for Monte Carlo simulation is furnished that randomly samples values for model parameters and writes them into a run-time language (command file) format which can then be utilized to execute individual PBPK models. Modifications to the PBPK model allow the desired output to be written to a data file for statistical analysis. The method presented in this paper is applied to a simple PBPK model for benzene disposition.

[1]  L. Lowry,et al.  Biological monitoring IV: Measurements in urine , 1989 .

[2]  C J Portier,et al.  Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[3]  B. Allen,et al.  Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. , 1989, Toxicology letters.

[4]  J. Filliben The Probability Plot Correlation Coefficient Test for Normality , 1975 .

[5]  R H Reitz,et al.  Physiologically based pharmacokinetic modeling with methylchloroform: implications for interspecies, high dose/low dose, and dose route extrapolations. , 1988, Toxicology and applied pharmacology.

[6]  R C Spear,et al.  Structure and parameterization of pharmacokinetic models: their impact on model predictions. , 1992, Risk analysis : an official publication of the Society for Risk Analysis.

[7]  Robert V. O'Neill,et al.  Application of error analysis to a Marsh Hydrology Model , 1980 .

[8]  L. Lowry,et al.  Horizons: Biological Monitoring IV: Measurements in Urine , 1989 .

[9]  R A Corley,et al.  Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.

[10]  M E Andersen,et al.  Development of a physiologically based pharmacokinetic model for chloroform. , 1990, Toxicology and applied pharmacology.

[11]  H A el-Masri,et al.  The use of physiologically-based pharmacokinetic/pharmacodynamic dosimetry models for chemical mixtures. , 1995, Toxicology letters.

[12]  John F. Young,et al.  A physiologically based pharmacokinetic computer model for human pregnancy. , 1994, Teratology.

[13]  F Y Bois,et al.  An analysis of exposure rate effects for benzene using a physiologically based pharmacokinetic model. , 1992, Regulatory toxicology and pharmacology : RTP.

[14]  Christopher J. Portier,et al.  Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride. , 1989 .

[15]  D G Gray,et al.  A physiologically based pharmacokinetic model for methyl mercury in the pregnant rat and fetus. , 1995, Toxicology and applied pharmacology.

[16]  L S Birnbaum,et al.  A physiological model for simulation of benzene metabolism by rats and mice. , 1989, Toxicology and applied pharmacology.

[17]  M E Andersen,et al.  A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. , 1981, Toxicology and applied pharmacology.

[18]  C C Travis,et al.  Pharmacokinetics of benzene. , 1990, Toxicology and applied pharmacology.

[19]  H J Clewell,et al.  Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[20]  H J Clewell,et al.  A physiologically based simulation approach for determining metabolic constants from gas uptake data. , 1986, Toxicology and applied pharmacology.

[21]  H. Leung,et al.  Use of physiologically based pharmacokinetic models to establish biological exposure indexes. , 1992, American Industrial Hygiene Association journal.

[22]  R C Spear,et al.  Mechanisms of benzene carcinogenesis: application of a physiological model of benzene pharmacokinetics and metabolism. , 1991, Toxicology letters.

[23]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[24]  R. L. Zielhuis,et al.  Phenol excretion as a measure of benzene exposure. , 1967, The Annals of occupational hygiene.

[25]  R C Spear,et al.  Modeling benzene pharmacokinetics across three sets of animal data: parametric sensitivity and risk implications. , 1991, Risk analysis : an official publication of the Society for Risk Analysis.

[26]  D J Paustenbach,et al.  A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. , 1990, Toxicology and applied pharmacology.

[27]  D J Paustenbach,et al.  A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. , 1988, Toxicology and applied pharmacology.

[28]  S. T. Sie,et al.  THE MEASUREMENT OF PHENOL IN URINE BY GAS CHROMATOGRAPHY AS A CHECK ON BENZENE EXPOSURE. , 1965, American Industrial Hygiene Association journal.

[29]  R C Spear,et al.  Comparison of three physiologically based pharmacokinetic models of benzene disposition. , 1991, Toxicology and applied pharmacology.

[30]  R B Conolly,et al.  Development of a physiologically based pharmacokinetic model describing 2-methoxyacetic acid disposition in the pregnant mouse. , 1995, Toxicology and applied pharmacology.

[31]  R. S. Thomas,et al.  Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. , 1996, American Industrial Hygiene Association journal.

[32]  M E Andersen,et al.  A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction. , 1993, Toxicology and applied pharmacology.